NCT06993753View on ClinicalTrials.gov

Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection

Active, not recruitingOBSERVATIONAL

Enrollment

4,350

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

April 15, 2026

Study Completion Date

March 31, 2027

Conditions

Respiratory Syncytial Viral (RSV) Infections

Trial Locations (1)

4215

Griffith University, Gold Coast

All Listed Sponsors

lead

Griffith University

OTHER

NCT06993753 - Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection | Biotech Hunter | Biotech Hunter